Paclitaxel therapy potentiates cold hyperalgesia in streptozotocin-induced diabetic rats through enhanced mitochondrial reactive oxygen species production and TRPA1 sensitization
- 1 March 2012
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pain
- Vol. 153 (3), 553-561
- https://doi.org/10.1016/j.pain.2011.11.019
Abstract
Summary Paclitaxel potentiates cold hyperalgesia in streptozotocin-induced diabetic rats through the combination of paclitaxel-induced increase in mitochondrial reactive oxygen species and diabetes-related overexpression of TRPA1. Diabetes comorbidities include disabling peripheral neuropathy (DPN) and an increased risk of developing cancer. Antimitotic drugs, such as paclitaxel, are well known to facilitate the occurrence of peripheral neuropathy. Practitioners frequently observe the development or co-occurrence of enhanced DPN, especially cold sensitivity, in diabetic patients during chemotherapy. Preclinical studies showed that reactive oxygen species (ROS) and cold activate transient receptor potential ankyrin-1 (TRPA1) cation channels, which are involved in cold-evoked pain transduction signaling in DPN. Additionally, paclitaxel treatment has been associated with an accumulation of atypical mitochondria in the sensory nerves of rats. We hypothesized that paclitaxel might potentiate cold hyperalgesia by increasing mitochondrial injuries and TRPA1 activation. Thus, the kinetics of paclitaxel-induced cold hyperalgesia, mitochondrial ROS production, and TRPA1 expression were evaluated in dorsal root ganglia of normoglycemic and streptozotocin-induced diabetic rats. In diabetic rats, paclitaxel significantly enhanced cold hyperalgesia in comparison to normoglycemic paclitaxel-treated control rats. These effects were prevented by N-acetyl-cysteine, a reducing agent, and by HC030031, an antagonist of TRPA1. In diabetic and control rats, paclitaxel treatment was associated with an accumulation of atypical mitochondria and a 2-fold increase in mitochondrial ROS production. Moreover, mRNA levels of glutathione peroxidase 4 and glutathione-S-reductase were significantly lower in diabetic groups treated with paclitaxel. Finally, TRPA1 gene expression was enhanced by 45% in diabetic rats. Paclitaxel potentiation of cold hyperalgesia in diabetes may result from the combination of increased mitochondrial ROS production and poor radical detoxification induced by paclitaxel treatment and diabetes-related overexpression of TRPA1.Keywords
This publication has 40 references indexed in Scilit:
- Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic painNeuroscience, 2011
- Role of TRP Channels in Pain SensationPublished by Springer Science and Business Media LLC ,2010
- TRPA1 Contributes to Cold HypersensitivityJournal of Neuroscience, 2010
- Modulation of inhibitory neurotransmission by the vanilloid receptor type 1 (TRPV1) in organotypically cultured mouse substantia gelatinosa neuronsPain, 2010
- Characterization of Two Runx1-Dependent Nociceptor Differentiation Programs Necessary for Inflammatory versus Neuropathic PainMolecular Pain, 2010
- Transient Receptor Potential A1 Is a Sensory Receptor for Multiple Products of Oxidative StressJournal of Neuroscience, 2008
- Transcriptional and functional profiles of voltage-gated Na+ channels in injured and non-injured DRG neurons in the SNI model of neuropathic painMolecular and Cellular Neuroscience, 2008
- The ROS Production Induced by a Reverse-Electron Flux at Respiratory-Chain Complex 1 is Hampered by MetforminJournal of Bioenergetics and Biomembranes, 2006
- A radical explanation for glucose-induced β cell dysfunctionJCI Insight, 2003
- Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic painPain, 1993